Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CDR132L in heart failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy
jRCT2031250305Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and left ventricular hypertrophy (LVH) comparing CDR132L + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in miR-132. Started Aug 2025; status: recruiting.
02
Drugs
CDR132L
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mid-range ejection fraction (HFmrEF)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on jRCT2031250305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250305.